For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are "equivalent" in terms of quality, efficacy and safety to an innovative reference medicinal product.
Scope of the Report:
This report focuses on the Monoclonal antibodies (mAbs) Biosimilars in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
The worldwide market for Monoclonal antibodies (mAbs) Biosimilars is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Hospira
- 3SBio
- Accord Healthcare
- AET Biotech
- Allergan
- Amega Biotech
- Others
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Erythropoietin (EPO)
- Human Growth Hormone (HGH)
- Granulocyte- Colony Stimulating Factor (G-CSF)
- Monoclonal Antibody (mAb)
- Insulin
- Interferon (IFN)
- Others
Market Segment by Applications, can be divided into
- Anti-Cancer
- Anti-Inflammatory/Autoimmune
There are 15 Chapters to deeply display the global Monoclonal antibodies (mAbs) Biosimilars market.
Chapter 1, to describe Monoclonal antibodies (mAbs) Biosimilars Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Monoclonal antibodies (mAbs) Biosimilars, with sales, revenue, and price of Monoclonal antibodies (mAbs) Biosimilars, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Monoclonal antibodies (mAbs) Biosimilars, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Monoclonal antibodies (mAbs) Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Monoclonal antibodies (mAbs) Biosimilars sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source